BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study For 456 women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback